Catalyst Health Economics Consultants

Hypertension

1. A comparison of the economic impact on the NHS of ramipril and enalapril in the treatment of essential hypertension.

Authors: JF Guest & VL Munro.
Source: British Journal of Medical Economics 1996; 10: 303-314.

View Abstract

2. Health-related quality of life impact of triple combinations of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in subjects with hypertension.

Presented at the 17th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Amsterdam, November 2014.

3. Health-related quality of life impact of triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension.

Authors: P Marques da Silva, U Haag, JF Guest, J Brazier, M Soro.
Source: Health and Quality of Life Outcomes 2015; 13(1):24. doi: 10.1186/s12955-015-0216-6.

View Abstract


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018